DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Adults with BMI ≥30, or BMI ≥27 with weight-related comorbidity (T2D, hypertension, dyslipidemia, sleep apnea, cardiovascular disease).
Wegovy FDA-approved eligibility: (1) Adult age (≥18); (2) BMI ≥30 (obesity) OR BMI ≥27 with at least one weight-related comorbidity — type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease; (3) March 2024 expansion: cardiovascular risk reduction in patients with established CVD and overweight/obesity regardless of T2D status. For insurance approval, most plans require 6-12 months of documented diet/exercise failure plus a comorbidity ICD-10 code. Off-label cosmetic weight loss (BMI <27) is not covered and increasingly audited. Pediatric Wegovy is FDA-approved for ages 12-17 with obesity — a separate pathway. Check our coverage matrix for plan-specific PA criteria.
Editorial answer reviewed by a board-certified clinician. Not medical advice. Coordinate treatment decisions with your prescriber.